Bertrand Johanna, Dannhoffer Luc, Antigny Fabrice, Vachel Laura, Jayle Christophe, Vandebrouck Clarisse, Becq Frédéric, Norez Caroline
Laboratoire Signalisation et Transports Ioniques Membranaires, Université de Poitiers-CNRS, Pôle Biologie Santé, 1 rue Georges Bonnet, 86073 Poitiers Cedex 9, France.
Service de Chirurgie Cardiothoracique, CHU La Milétrie, 2 rue de la Miletrie, 86021 Poitiers, France.
Eur J Pharmacol. 2015 Oct 15;765:337-45. doi: 10.1016/j.ejphar.2015.08.005. Epub 2015 Aug 8.
TRPC6 plays important human physiological functions, notably in artery and arterioles constriction, in regulation of vascular volume and in bronchial muscle constriction. It is implicated in pulmonary hypertension, cardiovascular disease, and focal segmental glomerulosclerosis and seems to play a role in cancer development. Previously, we identified Guanabenz, an α2-adrenergic agonist used for hypertension treatment (Wytensin®), as an activator of calcium-dependent chloride channels (CaCC) in human Cystic Fibrosis (CF) nasal epithelial cells by transiently increasing [Ca2+]i via an influx of extracellular Ca2+. In this study, using assays to measure chloride channel activity, we show that guanabenz is an activator of CaCC in freshly dissociated human bronchial epithelial cells from three CF patients with various genotypes (F508del/F508del, F508del/R1066C, F508del/H1085R). We further characterised the effect of guanabenz and show that it is independent of α-adrenergic receptors, is inhibited by the TRPC family inhibitor SKF-96365 but not by the TRPV family inhibitor ruthenium red. Using western-blotting, Ca2+ measurements and iodide efflux assay, we found that TRPC1 siRNA has no effect on guanabenz induced responses whereas TRPC6 siRNA prevented the guanabenz-dependent Ca2+ influx and the CaCC-dependent activity stimulated by guanabenz. In conclusion, we show that TRPC6 channel is pivotal for the activation of CaCC by guanabenz through a α2-adrenergic-independent pathway in human airway epithelial cells. We suggest propose a functional coupling between TRPC6 and CaCC and guanabenz as a potential TRPC6 activator for exploring TRPC6 and CaCC channel functions and corresponding channelopathies.
TRPC6发挥着重要的人体生理功能,尤其在动脉和小动脉收缩、血管容量调节以及支气管肌肉收缩方面。它与肺动脉高压、心血管疾病和局灶节段性肾小球硬化有关,并且似乎在癌症发展中起作用。此前,我们通过细胞外Ca2+内流短暂增加[Ca2+]i,鉴定出用于治疗高血压的α2-肾上腺素能激动剂胍那苄(Wytensin®)是人类囊性纤维化(CF)鼻上皮细胞中钙依赖性氯通道(CaCC)的激活剂。在本研究中,我们使用测定氯通道活性的方法,表明胍那苄是来自三名不同基因型(F508del/F508del、F508del/R1066C、F508del/H1085R)CF患者的新鲜解离的人支气管上皮细胞中CaCC的激活剂。我们进一步表征了胍那苄的作用,表明其作用独立于α-肾上腺素能受体,被TRPC家族抑制剂SKF-96365抑制,但不被TRPV家族抑制剂钌红抑制。使用蛋白质免疫印迹、Ca2+测量和碘外流测定,我们发现TRPC1 siRNA对胍那苄诱导的反应没有影响,而TRPC6 siRNA阻止了胍那苄依赖性的Ca2+内流以及胍那苄刺激的CaCC依赖性活性。总之,我们表明在人气道上皮细胞中,TRPC6通道对于胍那苄通过α2-肾上腺素能非依赖性途径激活CaCC至关重要。我们提出TRPC6与CaCC之间存在功能偶联,并且胍那苄作为潜在的TRPC6激活剂可用于探索TRPC6和CaCC通道功能以及相应的通道病。